Company Overview and News

0
India’s Subprime Mortgage Mania Can Quickly Turn to Panic - Bloomberg

2018-06-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HDFC 500010 HDFC

31
HDFC Bank may rely on Indian market for $2.3 billion share sale

2018-06-18 livemint
Mumbai: HDFC Bank Ltd, the world’s most expensive major lender, is considering relying entirely on the Indian market for a share sale that could raise as much as Rs 15,500 crore ($2.3 billion), people with knowledge of the matter said.
523405 DGLD MS.PRE MS.PRF MS.PRG 532636 IIFL HDFC MS.PRA CS UGLD HDFCBANK MS 500010 JMFINANCIL DSLV EDELWEISS VIIX CSSLF VIIZ 532922 CSGKF MS.PRI MS.PRK HDB 500180 ZIV USLV TVIX HDFC XIV

6
HDFC Bank said to mull relying on India in US$2.3 bil offer

2018-06-18 theedgemarkets
MUMBAI/HONG KONG (June 18): HDFC Bank Ltd, the world’s most expensive major lender, is considering relying entirely on the Indian market for a share sale that could raise as much as 155 billion rupees (US$2.3 billion), people with knowledge of the matter said.
HDB 500180 HDFCBANK HDFC 500010 HDFC

5
Will India ETFs Override Strong Dollar & High Oil Price?

2018-05-11 zacks
On account of the rising dollar prices, the Indian rupee has been trending down since the beginning of 2018. On May 7, the currency went down to its lowest in 15 months and was trading at 67.13 against the dollar.
500325 RELIANCE RIGD INFY HDFC 500010 HDFC RLNIY

0
Sebi moots shorter time period for IPO price announcement

2018-05-05 freepressjournal.in
New Delhi : Sebi on Friday proposed a slew of changes to public issue norms, including shorter time period for price band announcement and lesser disclosures about group companies at the time of IPOs.
HDFC 500010 HDFC

6
SEBI keeps HDFC AMC’s IPO in abeyance

2018-05-04 thehindubusinessline
HDFC AMC operates as a joint venture between Housing Development Finance Corporation and Standard Life Investments.
523405 HDB 500180 HDFCBANK IIFL HDFC 532636 500010 HDFC JMFINANCIL

24
Market Live: Sensex falls 250 pts, Nifty breaks 10,600; rupee extends losses

2018-05-04 moneycontrol
Earnings: Ambuja Cements has reported standalone profit at Rs 271.8 crore for the quarter ended March 2018, a growth of 10.3 percent over Rs 246.5 crore reported in year-ago.
BAJAJ-AUTO 500325 500820 500425 533150 RELIANCE ATB 532977 HDFC BHRQY AMBUJACEM ASIANPAINT 532215 532541 AMBUY AXISBANK 506590 RIGD PHILIPCARB 500412 BHARTIARTL 500010 RLNIY NIITTECH YESBANK HINDALCO CARBORUNIV AXB 532648 YYBKY 513375 AXBKY TIRUMALCHM HNDNF 532454 AXBA GODREJPROP 534809 PCJEWELLER HDFC 500440

0
HDFC Q4 profit rises 39% to Rs2,846 crore

2018-04-30 livemint
Housing Development Finance Corp. Ltd (HDFC) on Monday reported a net profit of Rs2,846 crore in the March 2018 quarter, up 39.2% from Rs2,044 crore in the year-ago quarter.
HDFC 500010 HDFC

18
HDFC Q4 profit jumps 39% to Rs 2,846 cr, exceeds expectations

2018-04-30 moneycontrol
HDFC or the Housing Development Finance Corporation reported a 39 percent jump in net profit to Rs 2,846 crore for the fourth quarter ending March 2018, exceeding expectations despite an increase in the provisions.
AXBKY AXBA ICICIBANK AXB AXISBANK 532174 IBN HDFC 500010 HDFC 532215 SBAZ

3
Fund-raising plans: HDFC, DHFL, India Glycols

2018-04-27 thehindubusinessline
The boards of directors of Housing Development Finance Corporation, Dewan Housing Finance and India Glycols will meet on Monday to consider fund-raising plans. The board of India Glycols will also consider the result for the quarter and full-year ended March 2018. HDFC and Dewan Housing will consider fund raising by way of further public issue of secured non-convertible debentures. The board of HDFC will also consider increase in the overall borrowing powers.
YESBANK DHFL INDIAGLYCO 511072 500201 532648 HDFC YYBKY 500010 HDFC

0
HDFC AMC net profit jumps 31% to Rs722 crore in FY18

2018-04-17 livemint
New Delhi: Leading mutual fund house HDFC Asset Management Company (AMC) on Tuesday reported a 31% jump in net profit at Rs722.61 crore in 2017-18 compared to Rs550.24 crore in the previous financial year.
HDFC 500010 HDFC

4
HDFC AMC net up 31% in FY18

2018-04-16 thehindubusinessline
Our Bureau HDFC Asset Management Co on Monday reported a 31 per cent jump in profit after tax at ₹722.61 crore for the fiscal 2017-18. Last year, the AMC had reported a net profit of ₹550.24 crore.
532505 HDFC UCOBANK 500570 500010 HDFC TATAMOTORS TTM

11
Eight of top 10 cos add Rs 83,672 crore in market cap

2018-04-15 moneycontrol
Eight of the 10 most valued Indian companies together added Rs 83,672 crore to their market valuation for last week, with IT major Tata Consultancy Services (TCS) leading the pack.
500325 RELIANCE HINDUNILVR HDFC TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD 500696 HDFCBANK TCS 500010 HDFC RLNIY SBAZ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...